Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion A Study Interrupted

被引：16
|
作者：
Sharfstein, Joshua M. [1 ]
Psaty, Bruce M. [2 ,3 ,4 ,5 ]
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[2] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[3] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[4] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[5] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2016年 / 315卷 / 10期
关键词：
CONFIDENTIALITY; TRIALS;
D O I：
10.1001/jama.2016.1461
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：984 / 986
页数：3
相关论文
共 50 条
  • [1] Naltrexone-bupropion for weight loss
    Thomas, Betsy
    Lindblad, Adrienne J.
    Luu, Thao
    Paige, Allison
    CANADIAN FAMILY PHYSICIAN, 2023, 69 (09) : 627 - 627
  • [2] Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors A Randomized Clinical Trial
    Nissen, Steven E.
    Wolski, Kathy E.
    Prcela, Lisa
    Wadden, Thomas
    Buse, John B.
    Bakris, George
    Perez, Alfonso
    Smith, Steven R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (10): : 990 - 1004
  • [3] Naltrexone-bupropion combination therapy for protracted abstinence dysphoria
    Williams, J
    Ziedonis, DM
    AMERICAN JOURNAL ON ADDICTIONS, 2003, 12 (03): : 270 - 272
  • [4] Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Response to Letter]
    Lyu, Young Sang
    Ahn, Hongyup
    Hong, Sangmo
    Park, Cheol-Young
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2025, 19 : 65 - 66
  • [5] Treatment with liraglutide or naltrexone-bupropion in patients with genetic obesity: a real-world study
    Welling, Mila S.
    de Groot, Cornelis J.
    Mohseni, Mostafa
    Meeusen, Renate E. H.
    Boon, Mariette R.
    van Haelst, Mieke M.
    van den Akker, Erica L. T.
    van Rossum, Elisabeth F. C.
    ECLINICALMEDICINE, 2024, 74
  • [6] Oral naltrexone-bupropion combination pharmacotherapy for methamphetamine use disorder: Pilot study protocol
    Moller, Carl I.
    Siefried, Krista J.
    Clifford, Brendan
    Acheson, Liam S.
    Brett, Jonathan
    Dunlop, Adrian J.
    Haber, Paul S.
    Christmass, Michael
    Lintzeris, Nicholas
    Morley, Kirsten
    Shoptaw, Steve
    Trivedi, Madhukar
    Ezard, Nadine
    DRUG AND ALCOHOL REVIEW, 2023, 42 : S121 - S122
  • [7] Safety and Effectiveness of Naltrexone-Bupropion in Korean Adults with Obesity: Post-Marketing Surveillance Study
    Lyu, Young Sang
    Ahn, Hongyup
    Hong, Sangmo
    Park, Cheol-Young
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 5255 - 5268
  • [8] Cardiovascular safety of naltrexone and bupropion
    Kang, Seema
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05): : 390 - 390
  • [9] The Naltrexone-Bupropion Combination Reduces the Prevalence of the Metabolic Syndrome and Improves Cardiometabolic Markers in At-Risk Subjects
    Erickson, Janelle
    Greenway, Frank
    Dunayevich, Eduardo
    Tollefson, Gary
    OBESITY, 2008, 16 : S139 - S139
  • [10] Naltrexone-bupropion combinations do not affect cocaine self-administration in humans*
    Regnier, Sean D.
    Stoops, William W.
    Lile, Joshua A.
    Alcorn III, Joseph L.
    Bolin, B. Levi
    Reynolds, Anna R.
    Hays, Lon R.
    Rayapati, Abner O.
    Rush, Craig R.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2023, 224
12345